In July, Roche had already obtained approval in Japan for Ronapreve (casirivimab and imdévimab), co-developed with the American Regeneron, for the treatment of mild to moderate forms of Covid-19 (archives). KEYSTONE / URS FLUEELER sda-ats
–
–This content was published on November 05, 2021 – 10:15
(Keystone-ATS)
Chugai, the Japanese subsidiary of the pharma giant Roche, reports that the Ronapreve antibody cocktail has obtained approval for a new indication in the Japanese archipelago, as a preventive treatment for symptomatic Covid-19.
It is about “preventing the development of a symptomatic Covid-19 for people in close contact” with patients suffering from the disease, explains Friday Chugai in a press release.
In July, Roche had already obtained approval in Japan for Ronapreve (casirivimab and imdévimab), co-developed with the American Regeneron, for the treatment of mild to moderate forms of Covid-19.
The global phase III study confirmed a reduced risk of disease for uninfected and asymptomatic Covid-19 positive people in close contact with sick people.
“Vaccines are the best way to prevent Covid-19,” said Chugai President and CEO Osamu Okuda. But Ronapreve is “an important option” for people who cannot be vaccinated or who do not fully respond to vaccination, due to illnesses or the drugs they are taking.
Subcutaneous administration may be carried out in addition to administration by intravenous infusion already approved.
Regeneron’s anti-Covid cocktail has already been authorized in emergency in the United States.
–
